"Thalidomide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
| Descriptor ID |
D013792
|
| MeSH Number(s) |
D02.241.223.805.810.800 D03.383.621.808.800 D03.633.100.513.750.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thalidomide".
Below are MeSH descriptors whose meaning is more specific than "Thalidomide".
This graph shows the total number of publications written about "Thalidomide" by people in this website by year, and whether "Thalidomide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 2 | 3 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 12 | 12 | 24 |
| 2018 | 20 | 13 | 33 |
| 2019 | 8 | 3 | 11 |
| 2020 | 4 | 0 | 4 |
| 2021 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Thalidomide" by people in Profiles.
-
The influence of leprosy-related clinical and epidemiological variables in the occurrence and severity of COVID-19: A prospective real-world cohort study. PLoS Negl Trop Dis. 2021 07; 15(7):e0009635.
-
COVID-19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast. Clin Exp Dermatol. 2021 10; 46(7):1344-1346.
-
Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 Pandemic. J Drugs Dermatol. 2021 May 01; 20(5):582-583.
-
Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action. Br J Clin Pharmacol. 2021 10; 87(10):3835-3850.
-
Use of Apremilast in Patients With Psoriatic Arthritis During the COVID-19 Pandemic: Comment on the Article by Mikuls et al. Arthritis Rheumatol. 2021 03; 73(3):547-548.
-
Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs. Dig Liver Dis. 2021 03; 53(3):277-282.
-
Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study. Int J Infect Dis. 2021 Feb; 103:507-513.
-
Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic. Dermatol Ther. 2020 11; 33(6):e14464.
-
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. Ann Hematol. 2020 Nov; 99(11):2589-2598.
-
Can roflumilast become steroid-sparing alternative in the treatment of COVID-19? Med Hypotheses. 2020 Nov; 144:110246.